Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00188_DB00758_nanopub.RA5FRN39VssUTZpPtIa5mBp97xANlU-NXUlNinlo2imE4#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00188_DB00758 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00188_DB00758 label "DDI between Bortezomib and Clopidogrel - Moderate CYP2C19 Inhibitors like bortezomib may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Avoid concurrent use of moderate CYP2C19 inhibitors with clopidogrel whenever possible. If such a combination must be used, monitor closely for evidence of reduced clinical response to clopidogrel. [drugbank_resource:DB00188_DB00758]" assertion.
- drugbank_resource:DB00188_DB00758 identifier "drugbank_resource:DB00188_DB00758" assertion.
- drugbank_resource:DB00188_DB00758 title "DDI between Bortezomib and Clopidogrel - Moderate CYP2C19 Inhibitors like bortezomib may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Avoid concurrent use of moderate CYP2C19 inhibitors with clopidogrel whenever possible. If such a combination must be used, monitor closely for evidence of reduced clinical response to clopidogrel." assertion.
- drugbank:DB00758 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00188_DB00758 assertion.
- drugbank:DB00188 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00188_DB00758 assertion.